NEXGEL, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
NEXGEL, INC. (NXGL) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $228.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-17
- 2026-06-30: Operating Lease, Right-of-Use Asset, Amortization Expense 6 month $228.00K.
- 2025-06-30: Operating Lease, Right-of-Use Asset, Amortization Expense 6 month $116.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month |
|---|---|
| 2026-06-30 | $228.00K 10-Q · filed 2026-08-17 |
| 2025-06-30 | $116.00K 10-Q · filed 2026-08-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |